viewSummit Therapeutics PLC

Summit Therapeutics PLC boosted by US patent for C-diff antibiotic

Summit Therapeutics PLC shares nudged higher in London as its new antibiotic for hospital superbug C.Diff got a further boost.....

C. difficile infection is a serious healthcare threat in hospitals and care homes with between 450,000 and 700,000 cases of CDI in the US annually.

Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) shares nudged higher in London as its new antibiotic for hospital superbug C.Diff got a further boost.

The US patent and trademark office have granted a "composition of matter" patent.

It gives a period of exclusivity for ridinilazole in the United States until at least December 1, 2029, with the possibility of being extended.

It's been a busy period for the firm and Glyn Edwards, chief executive, said: "This new patent grant in one of our potential major commercial markets substantially strengthens our intellectual property estate protecting our novel CDI antibiotic ridinilazole and supports our efforts to maximise the potential of this promising compound."

"We are focused on advancing our CDI and DMD programmes and today's news, combined with the recently announced expansion of our PhaseOut DMD trial, highlights their continuing excellent progress as we seek to have a meaningful impact on the lives of patients living with these serious diseases."

In a Phase 2 clinical trial, ridinilazole showed statistical superiority over vancomycin - the standard of care medicine -  in rates of sustained clinical response, an endpoint that captures both initial cure and recurrence of the disease.

And earlier this week, shares rose after the FDA allowed the company to broaden the scope of its phase II clinical trial of its drug ezutromid, formerly SMT C1100, for Duchenne muscular dystrophy  to trial sites in the US.

Summit shares added 0.38% to stand  at 131p.

Quick facts: Summit Therapeutics PLC

Price: 23 GBX

Market: AIM
Market Cap: £36.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...



Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read